|Molecular Vision 2006;
Received 27 April 2005 | Accepted 18 January 2006 | Published 22 February 2006
Tubedown-1 (Tbdn-1) suppression in oxygen-induced retinopathy and in retinopathy of prematurity
Robert L. Gendron,1 William V.
Good,2 Ewa Miskiewicz,1 Stephanie Tucker,1 Dale L.
Phelps,3,4 Hélène Paradis1
1Division of Basic Medical Sciences, Department of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; 2Smith Kettlewell Eye Research Institute, San Francisco, CA; Departments of 3Pediatrics and 4Ophthalmology, University of Rochester School of Medicine and Dentistry, Rochester, NY
Correspondence to: Robert L. Gendron, Division of Basic Medical Sciences, Department of Medicine, Memorial University of Newfoundland, St. John's, NL, A1B 3V6, Canada; Phone: (709) 777-8554; FAX: (709) 777-8619; email: email@example.com
Purpose: Identification of unique proteins involved in retinopathy of prematurity (ROP) may facilitate new and more effective diagnostic tools and molecular-based treatments for ROP. Tubedown-1 (Tbdn-1), a novel homeostatic protein which copurifies with an acetyltransferase activity, is expressed in normal retinal endothelium and is specifically suppressed in retinal endothelial cells from patients with proliferative diabetic retinopathy. Furthermore, recent in vivo knockdown studies in mice have revealed that Tbdn-1 is important for retinal blood vessel homeostasis and for preventing retinal neovascularization in adults. The purpose of the present study was to determine if the expression pattern of Tbdn-1 is altered during oxygen-induced retinal neovascularization in mice and in a specimen of stage 3 human ROP.
Methods: Specimens of oxygen-induced retinal neovascularization in mice, and a single specimen of active stage 3 ROP were studied by immunohistochemistry and digital image analysis using antibodies raised against Tbdn-1 and other blood vessel markers.
Results: The pattern of Tbdn-1 expression during the course of oxygen-induced retinal neovascularization in mice suggests a regulating role in neonatal retinopathy. Retinal lesions from oxygen-induced retinal neovascularization in mice display suppression of retinal endothelial Tbdn-1 protein expression in conjunction with an increase in expression of proliferating cell nuclear antigen (a marker of proliferation) and α smooth muscle actin (a marker of myofibroblastic cells). Abnormal blood vessels within vitreoretinal neovascular lesions in a human specimen of active stage 3 ROP did not show Tbdn-1 protein expression.
Conclusions: These results suggest that the loss of retinal endothelial Tbdn-1 expression may be a contributing factor in retinal blood vessel proliferation in ROP.
Retinopathy of prematurity (ROP) remains a leading cause of vision impairment in children in the United States . The need for investigating new molecular-based therapies for ROP is exemplified by the recently completed Early Treatment for ROP study (ETROP) . That trial demonstrated that early treatment for high risk ROP resulted in better outcomes than traditional timing, yet 9.1% of the eyes in the Early Treatment arm still experienced retinal detachments or similar complications leading to severe vision loss. Thus, even with more optimally timed treatment, thousands of children worldwide are still blinded by the disease. In ROP, retinal blood vessels fail to develop to the peripheral areas of the retina, and a demarcation zone is thus created, dividing vascularized from avascular retina [3,4]. In mild cases of ROP, the demarcation appears as a line, but in severe cases, neovascularization occurs in the demarcation line or area. This neovascularization may further progress to cicatricial changes, which, in turn, can eventually lead to either a partial or total retinal detachment . Since current treatments involve ablation of peripheral retina, and because infants are still blinded by the disease despite adequate treatment, further work is needed to explore new molecular-based therapies for ROP.
The molecular sequence of events leading to ROP is complex. The transition from an in utero arterial oxygen tension (PaO2) of 30 or less to an extrauterine PaO2 of 80 or more occurs within minutes of birth. The avascular regions of a premature infant's partially vascularized retina mount a neovascularization response to counter the endarterial vasoconstriction occurring as a result of increased systemic oxygenation . Several growth and transcription factors, especially those involved in the responses to hypoxia and hyperoxia such as vascular endothelial growth factor (VEGF) and hypoxia-inducible factor (HIF-1α), have been described as potential angiogenic regulators of ROP [3,4,6,7]. Low serum levels of insulin-like growth factor (IGF-1) have been linked to the development of ROP . IGF-1 is important for retinal vascular development and regulates VEGF-induced survival signaling pathway in retinal endothelial cells which most likely plays a key role in the neovascularization seen in ROP . Other proteins such as platelet-derived growth factor BB (PDGF-BB), the angiopoietins (Ang-1 and Ang-2), and the Tie receptors (Tie-1 and Tie-2) are important molecules for controlling development of the vascular architecture and may play key roles in retinal neovascularization [9-11]. Any or all of these molecules and related processes may play a role in the pathogenesis of human ROP.
Work on molecular mechanisms in the ROP disease process have focused on growth factors, but proteins homeostatic to retinal blood vessels could also be important in averting the disease process in ROP. One such protein is Tubedown-1 (Tbdn-1), present in stable retinal vascular beds. Tbdn-1 is a mammalian homolog of the yeast acetyltransferase subunit Nat1 that is regulated during vascular development . While Tbdn-1 expression is restricted to few vascular beds in adults including normal ocular endothelial cells, atrial endocardium, blood vessels of regressing ovarian follicles, and bone marrow capillaries, Tbdn-1 expression is suppressed in retinal blood vessels in patients with proliferative diabetic retinopathy (PDR) [12,13]. Our laboratories have recently generated a binary antisense Tbdn-1 (Astbdn-1) transgenic mouse model driven by the Tie-2 pan-endothelial promoter, which enables conditional knockdown of Tbdn-1 protein expression in endothelial cells. Tbdn-1 knockdown animals display a phenotype that is restricted to the retina and characterized by neovascular proliferative retinopathy . Our Tbdn-1 knockdown model has provided in vivo evidence for the requirement of Tbdn-1 expression for the maintenance of normal retinal vascular homeostasis . In the present study, we have addressed whether Tbdn-1 protein expression becomes altered in oxygen-induced retinopathy in mice and have assessed the state of Tbdn-1 expression in a case of stage 3 neovascular ROP in humans.
Oxygen-induced retinopathy in mice
All mouse tissues used in this study were obtained from wild type C57BL/6 mice using procedures adherent to the Canadian Council on Animal Care. Neonatal mice were reared in normoxic conditions or in modified ambient oxygen concentrations (75% oxygen) for five days from postnatal (P) day 7 followed by normoxia for periods of time designed to induce retinal neovascularization as previously described . In our studies, eyes from 4 to 14 mice harvested at each point from P14 through P26 of normoxia or hyperoxia were analyzed by immunohistochemistry. Normal and hyperoxia-treated mouse eyes were fixed in 4% paraformaldehyde, embedded in paraffin, and processed for histology and immunohistochemistry as previously described in the literature [14,16]. Sections were stained for morphological analysis with hematoxylin and eosin (H&E) or for immunohistochemical analysis with different antibodies as will be described. Antibodies used for immunohistochemistry included the following: Mouse anti-Tbdn-1 serum MS.C10-20TD , the mouse monoclonal anti-α smooth muscle actin (ASMA) antibody (dilution of 1/100; Sigma Immunochemicals, St. Louis, MO), and rabbit anti-proliferating cell nuclear antigen (PCNA; diluted 1:25, Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Mouse antibodies were applied following a 30 min incubation in rabbit antimouse blocking preparation. The sections were rinsed in the appropriate concentration of TBS (10 mM Tris-HCl, pH 7.6, 150 mM NaCl), and reactions were developed using conjugated species-specific secondary antibodies. Red color reactions for Tbdn-1 and ASMA staining were generated using naphthol-AS-MX phosphate in the presence of fast red and levamisole (to block endogenous tissue alkaline phosphatase activity). Dark brown color reactions for PCNA staining were generated using diaminobenzidine (DAB) in the presence of hydrogen peroxide (sections had been pretreated with hydrogen peroxide to quench endogenous peroxidase activity). Reacted sections were lightly counterstained using a 0.5% aqueous solution of methyl green, rinsed in water, dried, and mounted in Permount (Fisher, Pittsburgh, PA).
Immunohistochemistry of Tbdn-1 expression in human ROP
Tbdn-1 expression was analyzed in one eye specimen from a premature infant with stage 3 ROP. The ROP case was as follows: 471 g birth weight, 27.5 weeks at birth, small for gestational age twin. The patient was examined regularly for ROP from age five weeks to the time of death at 48.5 weeks. One week before death, ROP was still active, showing zone II, stage 3 in both eyes without plus disease. The expression of Tbdn-1 in the ROP specimen was compared to Tbdn-1 staining in sections from an eye from a 19-week human fetus without ROP and to the level of staining found in two previous studies of normal human retinal blood vessels [13,16]. Research on human specimens followed the tenets of the Declaration of Helsinki at all times. All human eye tissue specimens were obtained and studied under the approval of the Institutional Review Boards of the authors' institutions (Smith Kettlewell Eye Research Institute, San Francisco, CA; University of Rochester, Rochester, NY; and Memorial University of Newfoundland, St. John's, Canada). Eyes from the 19-week human fetus without ROP and eyes from the ROP patient were procured at autopsy. The eyes then were fixed in formalin, processed, and embedded in paraffin blocks, and sectioned. Sections were deparaffinized, rehydrated, and subjected to immunohistochemistry for Tbdn-1 expression using Ab1272 antibody and for α-tubulin using an anti-α-tubulin specific mouse monoclonal antibody (Sigma Immunochemicals). Immunohistochemistry using the anti-Tbdn-1 chicken IgY antibody (Ab1272) as describedin the literature [12,13,16]. Red color reactions for Tbdn-1 and for α-tubulin staining were generated using aminoethylcarbazole (AEC) in the presence of hydrogen peroxide (sections had been pretreated with hydrogen peroxide to quench endogenous peroxidase activity). Reacted sections were not counterstained (in order to be able to detect low staining levels in Tbdn-1 cases), rinsed in water, dried, and mounted in Permount (Fisher, Pittsburgh, PA).
Data collection and analysis
From P14-P26 normoxia-reared neonatal mice (n=31) or P14-P26 modified ambient oxygen-reared neonatal mice (n=54), approximately 100 sections per eye were prepared, registered, and stored in serial or adjacent order. Every 15th section was stained with H&E to verify normal morphology in the controls and to map the retinal pathology in hyperoxia-treated mice. Tbdn-1 and marker analysis (ASMA, PCNA) was performed in at least three separate experiments on sections serial to those containing retinal lesions from hyperoxia-reared mice (as determined by H&E staining) and sections from the same area of the retina in control normoxia-reared mice. All sections were viewed and photographed using a Zeiss Photomicroscope system (Carl Zeiss Canada Ltd., Toronto, Canada) interfaced with a QImaging digital video camera attachment. Between three to six representative digital images from normoxia controls and hyperoxia-treated mice were processed with Improvision Openlab (version 3) and Adobe Photoshop (version 7) software for quantitation of the staining. Values were expressed as the mean percentage of the control±standard error (SEM in percentage). Data were statistically analyzed by Student's t-test. Intensity of Tbdn-1 staining in retinal blood vessels and background staining (from the inner plexiform layer area) was measured by determining red color intensity using Openlab software. Background measurements, which were similar for all specimens examined, were subtracted from Tbdn-1 retinal blood vessel staining measurements. ASMA (red) and PCNA (brown) staining intensity was measured using the magic wand and pixels measurement tool of the histogram function in Adobe Photoshop as described previously . Staining intensity was expressed in means of pixels per unit area (±SEM) where unit areas are defined as micrographs of equivalent dimension taken at equivalent magnification and light intensity. For ASMA and PCNA staining, not all control retina sections contained ASMA- or PCNA-expressing cells. As a result, the numbers for quantitative analysis were, respectively, limited to the numbers described in the figure legends. Micrographs shown in Figure 1 and Figure 2 are representative experiments of data quantified and presented in Figure 3 and Figure 4, respectively.
Tbdn-1 expression is suppressed during oxygen-induced retinopathy
Tbdn-1 has been characterized as a retinal endothelial homeostatic factor that blocks or prevents retinal neovascularization in an adult mouse model . To characterize Tbdn-1 expression in neonatal retinal neovascularization, we studied the oxygen-induced retinopathy mouse model. Retinal neovascularization in the mouse oxygen-induced retinopathy model has previously been reported to be maximal between P17-P21 . To determine if Tbdn-1 may be involved in oxygen-induced retinopathy, we rationalized that an assessment of Tbdn-1 expression between P14 and P26 would be most informative in evaluating if Tbdn-1 could play a role in neonatal retinal neovascularization since changes in Tbdn-1 expression might precede maximal neovascularization. Neonatal wild type C57BL/6 mice reared in hyperoxia revealed a phenotype consistent with previous reports  and characterized by the development of retinal lesions displaying retinal thickening, retinal membranes with neovascularization and fibrovascular growth (Figure 1B). Retinal pathology was observed as early as P14 and was maximal from P17 to P21. At postnatal age P26, most of the retinal neovascularization had regressed but a few areas still displayed pathology. In contrast, normoxia-reared control mice do not show any ocular pathology (Figure 1A).
In order to spatially and temporally quantitate changes in expression of retinal endothelial Tbdn-1 during oxygen-induced retinal neovascularization, Tbdn-1 immunostaining and methodology was used to measure immunohistochemical chromogen intensity in retinal blood vessels. Neonatal mice reared in elevated levels of oxygen showed significant decreases in expression of Tbdn-1 in proliferative retinal blood vessels of retinal lesions at all times examined (P14-P26) as compared to retinal blood vessels of age-matched control normoxia reared mice (Figure 1C,D, Figure 2). Quantitation of Tbdn-1 immunostaining in the vessels was carried out at three time points: P14-P16 for the initial neovascularization period, P17-P21 for the maximal neovascularization period, and P26 for the final or late neovascularization period. Quantitation of Tbdn-1 immunostaining was also divided in the oxygen-induced retinas into areas of distinct retinal lesions and the areas between these called "non-lesions". Quantitation of Tbdn-1 immunostaining in vessels of retinal lesions prior to (P14-P16), during (P17-P21), and shortly after maximal retinal neovascularization (P26) revealed that Tbdn-1 levels were reduced to 24% to 19% of control (Figure 2). Interestingly, Tbdn-1 expression in retinal blood vessels in areas outside the retinal lesions was also significantly suppressed prior to (P14-16: 48% of control) and during maximal neovascularization (P17-P21: 60% of control) compared to normoxia-reared mice (Figure 2). Therefore, Tbdn-1 suppression outside the retinal lesions was not as pronounced as the suppression observed in areas of retinal pathology (Figure 2). In contrast, at P26 in the hyperoxia-reared mice, Tbdn-1 levels outside the retinal lesions did not differ significantly from control room air-reared mice (Figure 2), indicating that Tbdn-1 levels were relatively restored at P26.
To further characterize the hyperoxia-induced retinal lesions, expression patterns of ASMA, a myofibroblast cell marker, and PCNA, a proliferating cell marker, were also analyzed by immunohistochemistry. A significantly higher level of expression of ASMA was detected in larger caliber abnormal blood vessels of the proliferative fibrovascular lesions of retinas of oxygen-reared mice when compared with little or no ASMA staining in retinal blood vessels of the examined eye sections of control mice reared in normoxia conditions (Figure 3, Figure 4). Nuclear expression of PCNA was significantly increased in endothelial cells in cross-sections of blood vessels of the retinal lesions of oxygen-induced animals compared to control animals which showed low levels of PCNA expression (Figure 3, Figure 4).
TBDN-1 expression is suppressed during retinopathy of prematurity in human
TBDN-1 immunolocalization was performed on a human fetus eye specimen (19 weeks age gestation) and a stage 3 ROP specimen to determine if TBDN-1 is expressed in pathological retinal blood vessels during the neovascularization phase of stage 3 ROP. H&E staining of sections of the ROP specimen revealed extensive inner retinal and vitreoretinal neovascularization consistent with stage 3 disease (Figure 5A). Eye sections from the ROP patient showed a lower level of expression of endothelial TBDN-1 protein in the diseased neovascular areas of the vitreal-retinal regions (Figure 5B,C) as compared to TBDN-1 levels expressed by blood vessels within Cloquet's Canal (Figure 5D) and tunica vasculosa lentis (Figure 5E) in an eye specimen from a 19 week human fetus without ROP, or compared to normal adult retinal vessels (not shown) and normal mouse neonate retinal vessels (Figure 1, Figure 2). Although there was faint TBDN-1 staining present in ROP blood vessels (Figure 5B,C), the level of staining was clearly lower than that observed in the specimen without ROP (Figure 5D,E) and slightly above the background levels observed in ROP sections incubated with a negative control IgY reagent (Figure 5F). As a positive immunohistochemistry control, eye section from the ROP patient showed a high level of expression of endothelial α-tubulin protein both in the diseased neovascular areas of the vitreal-retinal regions (Figure 5G) and in the nonpathological areas of the retina. These results suggest that Tbdn-1 may not be expressed highly in abnormal proliferating vitreoretinal blood vessels in ROP.
Our results show that Tbdn-1 expression is downregulated in the oxygen-induced experimental mouse model of retinopathy. The phenotype observed in neonatal wild type C57BL/6 mice reared in hyperoxia conditions was consistent with the response described in previous literature  and was characterized by the formation of retinal lesions displaying pronounced retinal thickening, extensive retinal neovascularization, and fibrovascular retinal growth. We previously observed that endothelial Tbdn-1 expression increases before the vascular regression that mediates the remodeling of the hyaloid vasculature in the developing mouse vitreous . Our Tbdn-1 knockdown model has demonstrated that Tbdn-1 serves to block retinal neovascularization . Knockdown of Tbdn-1 in blood vessels in adult mice leads to the development of fibrovascular lesions accompanied by significantly increased neovascularization and thickening of the retina and choroid similar to human proliferative retinopathies . Therefore, in the present study, we hypothesized that downregulation of Tbdn-1 would precede maximal neovascularization in the oxygen-induced model of retinopathy. In the mouse oxygen-induced retinopathy model, maximal pathology peaks between P17-P21 and thereafter regresses . Indeed we found that general suppression of Tbdn-1 in the retinal blood vessels (outside the lesions) occurs prior to (P14-P16) and during (P17-P21) maximal retinal neovascularization in the oxygen-induced retinopathy model. In addition, a marked suppression of Tbdn-1 (up to 81%) in the blood vessels of the retinal lesions is consistently observed at all time points examined (P14-P26). These results suggest that Tbdn-1 loss may be involved in predisposing neonatal mice to retinal neovascularization.
The retinal pathology in hyperoxia-induced mice is also accompanied by a progressive increase in retinal tissue thickness. Although different in many ways to human ROP, the pathology seen in the oxygen-induced model is somewhat reminiscent of the retinal thickening seen in proliferative retinopathies in humans [18,19]. In addition, the hyperoxia-induced retinal lesions were similar in morphological appearance to those lesions we have observed in Tbdn-1 knockdown mice  in which retinal neovascularization of different layers of the retina is accompanied by significant retinal thickening. Of importance is the finding that the decrease in Tbdn-1 expression in proliferative retinal blood vessels of retinal lesions of hyperoxia-reared mice was accompanied by an increase in retinal blood vessel expression of the myofibroblast marker ASMA, and an increase in retinal endothelial expression of the proliferating cell marker PCNA. Myofibroblasts expressing ASMA are thought to be involved in the formation of retinal lesions possessing contractile forces that promote retinal detachment [20,21]. This pattern of suppressed retinal endothelial Tbdn-1 combined with upregulated blood vessel ASMA in retinal lesions of hyperoxia-reared mice was akin to the pattern observed in the Tbdn-1 knockdown retina . Furthermore, the upregulated retinal endothelial PCNA is similar to that seen previously in vitreoretinal neovascularization of TGF-β2 null fetal retinas, which is also accompanied by a suppression of Tbdn-1 expression in the hyaloid vessels . These results indicate that Tbdn-1 loss and extensive remodeling of vitreoretinal blood vessels occurs in hyperoxia-induced retinopathy in mice. Although the mouse model of oxygen-induced retinopathy differs in several ways from human ROP, these results support a possible role of suppression of Tbdn-1 expression in the pathogenesis of ROP.
Human stage 3 ROP and appropriate age-matched controls are very difficult to obtain. In this study we were fortunate to have access to a specimen of appropriately fixed and histologically processed ROP and to observe a lower level of expression of TBDN-1 in this stage 3 ROP specimen compared to one 19 week human fetal eye specimen. The ROP specimen showed a low level of expression of endothelial TBDN-1 protein in the diseased neovascular areas of the vitreal-retinal regions. Many of these abnormal blood vessels had grown into the vitreous. We compared this staining level to the level of TBDN-1 expressed by blood vessels within Cloquet's Canal and the tunica vasculosa lentis, which are both regions suspended in the vitreous body, in the fetal eye specimen from a subject without ROP. The absence of TBDN-1 expression in blood vessels of the ROP specimen was not due to the loss of blood vessel endothelial cells or to a loss of immunoreactivity of the tissue sections, because the ROP sections stained highly with an antibody to the ubiquitous pan tissue α-tubulin. Moreover, we have studied Tbdn-1 expression postnatally in mice and have found high levels of Tbdn-1 expression in retinal blood vessels of developing mice at stages analogous to the human ROP specimens analyzed (Figure 1). Furthermore, retinal endothelial TBDN-1 expression remains high in normal human adults . Interestingly, sections of the eye from the ROP patient also showed a lower level of expression of endothelial TBDN-1 protein in nondiseased deeper retinal areas and the diseased neovascular areas. This suggests that a potential pan retinal effect in human ROP may include the suppression of TBDN-1 expression in regions other than those involved in immediate neovascular pathology. We have reported that a pan retinal effect occurs in the Tbdn-1 knockdown retina in which the suppression of retinal blood vessel basement membrane heparan sulfate proteoglycan is found throughout the Tbdn-1 suppressed retina as opposed to only in the neovascularized retinal lesions . Previous studies by Berkowitz et al.  have also demonstrated that a pan retinal response to a carbogen challenge does indeed occur in the rat model of oxygen-induced retinal neovascularization. Collectively these studies suggest that a pan retinal effect could be a hallmark of oxygen-induced retinopathy and possibly also of ROP. Our results, although based only upon a single specimen, suggest that TBDN-1 may not be expressed in abnormal proliferating vitreoretinal blood vessels in ROP.
Given the possible link between tissue oxygen regulation and development of vitreoretinal neovascularization in ROP, a mechanistic explanation of the possible role of loss of Tbdn-1 expression in ROP emerges. Members of the Tbdn-1 family of molecules likely function in a holoenzyme complex and might regulate blood vessel proliferation by affecting the stability and the activity of proteins involved in regulating angiogenesis through acetylation. The acetyltransferase ARD1, which binds the mammalian Tbdn-1 homolog NAT-1, has been suggested to play a role in the targeted degradation and thus removal of HIF-1α in mammals . It is now well established that HIF-1α regulates VEGF expression during hypoxia and can promote blood vessel proliferation through its induction of VEGF . Suppression or absence of one or more of the acetyltransferase holoenzyme complex binding partners which regulate HIF-1α stability might disrupt if not alter activity of the complex. The disruption of acetyltransferase complexes involving ARD1 or Tbdn-1 might promote the stabilization of HIF-1α and increase the production of growth factors promoting neovascularization in the retina. A study of the expression and function of Tbdn-1 family proteins in conjunction with the HIF-1α pathway in both the oxygen-induced retinal neovascularization model and in human ROP would be informative to address these hypotheses.
The suppression of Tbdn-1 expression in retinal endothelium in retinal lesions of the hyperoxia-induced retinopathy model provides further evidence for an important role of Tbdn-1 expression for the maintenance of retinal blood vessel homeostasis through suppression of abnormal retinal blood vessel growth. Our transgenic Tbdn-1 knockdown mouse model, which displays neovascular proliferative retinopathy, provides in vivo confirmatory evidence for the requirement of Tbdn-1 expression for the maintenance of normal retinal vascular homeostasis . This, together with our preliminary but compelling evidence of TBDN-1 suppression in the retinal endothelium in a patient with ROP, supports our hypothesis of a contributing role for loss of TBDN-1 expression in the progression of neovascularization in proliferative retinopathies. TBDN-1 may serve as a valuable pathway for developing new therapies aimed at controlling ROP and other proliferative retinopathies.
We thank Lisa C. Adams and Dana S. Wall for technical assistance with histology and immunohistochemistry. We are grateful for support from Canadian Institutes of Health Research Operating Grants, Foundation Fighting Blindness-Canada Operating Grant, Canada Foundation for Innovation (HP, RLG), Atlantic Canada Opportunity Agency (Memorial University of Newfoundland), and NIH (U10EY012472 to WVG).
1. Steinkuller PG, Du L, Gilbert C, Foster A, Collins ML, Coats DK. Childhood blindness. J AAPOS 1999; 3:26-32.
2. Good WV, Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc 2004; 102:233-48.
3. Smith LE. Pathogenesis of retinopathy of prematurity. Growth Horm IGF Res 2004; 14:S140-4.
4. Smith LE. Pathogenesis of retinopathy of prematurity. Semin Neonatol 2003; 8:469-73.
5. Wheatley CM, Dickinson JL, Mackey DA, Craig JE, Sale MM. Retinopathy of prematurity: recent advances in our understanding. Br J Ophthalmol 2002; 86:696-700.
6. Ozaki H, Yu AY, Della N, Ozaki K, Luna JD, Yamada H, Hackett SF, Okamoto N, Zack DJ, Semenza GL, Campochiaro PA. Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression. Invest Ophthalmol Vis Sci 1999; 40:182-9.
7. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH, Yoo MA, Song EJ, Lee KJ, Kim KW. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 2002; 111:709-20.
8. Hellstrom A, Perruzzi C, Ju M, Engstrom E, Hard AL, Liu JL, Albertsson-Wikland K, Carlsson B, Niklasson A, Sjodell L, LeRoith D, Senger DR, Smith LE. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A 2001; 98:5804-8.
9. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998; 125:1591-8.
10. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997; 277:48-50.
11. Hackett SF, Ozaki H, Strauss RW, Wahlin K, Suri C, Maisonpierre P, Yancopoulos G, Campochiaro PA. Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization. J Cell Physiol 2000; 184:275-84.
12. Gendron RL, Adams LC, Paradis H. Tubedown-1, a novel acetyltransferase associated with blood vessel development. Dev Dyn 2000; 218:300-15.
13. Gendron RL, Good WV, Adams LC, Paradis H. Suppressed expression of tubedown-1 in retinal neovascularization of proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2001; 42:3000-7.
14. Wall DS, Gendron RL, Good WV, Miskiewicz E, Woodland M, Leblanc K, Paradis H. Conditional knockdown of tubedown-1 in endothelial cells leads to neovascular retinopathy. Invest Ophthalmol Vis Sci 2004; 45:3704-12.
15. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, D'Amore PA. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994; 35:101-11.
16. Paradis H, Liu CY, Saika S, Azhar M, Doetschman T, Good WV, Nayak R, Laver N, Kao CW, Kao WW, Gendron RL. Tubedown-1 in remodeling of the developing vitreal vasculature in vivo and regulation of capillary outgrowth in vitro. Dev Biol 2002; 249:140-55.
17. Lehr HA, Mankoff DA, Corwin D, Santeusanio G, Gown AM. Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem 1997; 45:1559-65.
18. Speicher MA, Danis RP, Criswell M, Pratt L. Pharmacologic therapy for diabetic retinopathy. Expert Opin Emerg Drugs 2003; 8:239-50.
19. Panozzo G, Gusson E, Parolini B, Mercanti A. Role of OCT in the diagnosis and follow up of diabetic macular edema. Semin Ophthalmol 2003; 18:74-81.
20. Bochaton-Piallat ML, Kapetanios AD, Donati G, Redard M, Gabbiani G, Pournaras CJ. TGF-beta1, TGF-beta receptor II and ED-A fibronectin expression in myofibroblast of vitreoretinopathy. Invest Ophthalmol Vis Sci 2000; 41:2336-42.
21. Gandorfer A, Rohleder M, Kampik A. Epiretinal pathology of vitreomacular traction syndrome. Br J Ophthalmol 2002; 86:902-9.
22. Berkowitz BA, Penn JS. Abnormal panretinal response pattern to carbogen inhalation in experimental retinopathy of prematurity. Invest Ophthalmol Vis Sci 1998; 39:840-5.